Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions

Brain

Volumn 117, Issue 1, 1994, Pages 49-58

  Davie, C A ^a   Hawkins, C P ^a   Barker, G J ^a   Brennan, A ^a   Tofts, P S ^a   Miller, D H ^a   Mcdonald, W I ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Demyelination; Lipids; Multiple sclerosis; N acetylaspartate; NMR spectroscopy

Indexed keywords

CREATINE; GADOLINIUM PENTETATE; LIPID; MYELIN; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BRAIN INJURY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DEMYELINATION; FOLLOW UP; HUMAN; MULTIPLE SCLEROSIS; NEURORADIOLOGY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; WHITE MATTER;

ADULT; ASPARTIC ACID; CREATINE; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; MULTIPLE SCLEROSIS; ORGANOMETALLIC COMPOUNDS; PENTETIC ACID;

EID: 0028265609     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/117.1.49     Document Type: Article

References (50)

1. Adams CWM, Poston RN, Buk SJ. Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis. J Neurol Sci 1989; 92: 291-306.
2. Allen I.V. Pathology of multiple sclerosis. In: Matthews WB, Compston A, Allen IV, Martyn CM, editors. McAlpine’s multiple sclerosis. Second edition. Edinburgh: Churchill Livingstone, 1991: 341-78.
3. Arnold DL. Reversible reduction of A-acetylaspartate after acute central nervous system damage. In:Proceedings of the Eleventh Annual Meeting of the Society for Magnetic Resonance in Medicine. 1992; 1: 643.
4. Arnold DL, Matthews PM, Francis GS, O’Connor J, Antel JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992; 31: 235-41.
5. Barratt HJ, Miller D, Rudge P. The site of the lesion causing deafness in multiple sclerosis. Scand Audiol 1988; 17: 67-71.
6. Behar KL, Ogino T. Assignment of resonance in the ‘H spectrum of rat brain by two-dimensional shift correlated and J-resolved NMR spectroscopy. Magn Reson Med 1991; 17: 285-303.
7. Birken DL, Oldendorf WH. A-Acetyl-L-aspartie acid: a literature review of a compound prominent in 'H-NMR spectroscopic studies of brain [review]. Neurosci Biobehav Rev 1989; 13: 23-31.
8. Brenner RE, Munro PMG, Williams SCR, Bell JD, Barker GJ, Hawkins CP et al. The proton NMR spectrum in acute EAE: the significance of the change in the Cho:Cr ratio. Mag Reson Med 1993; 29: 737-45.
9. Bruhn H, Frahm J, Merboldt KD, Hânicke W, Hanefeld F, Christen HJ et al. Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol 1992; 32: 140-50.
10. Callies R, Sri-pathmanathan RM, Ferguson DYP, Brindle KM. The appearance of neutral lipid signals in the !H NMR spectra of a myeloma cell line correlates with the induced formation of cytoplasmic lipid droplets. Magn Reson Med 1993; 29: 546-52.
11. Charcot M. Histologie de la sclérose en plaques. Gaz Hôsp 1868; 141: 554-5, 557-8.
12. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH et al. Detection of lipid in the brain of healthy subjects by proton NMR spectroscopy. In: Proceedings of the Eleventh Annual Meeting of the Society for Magnetic Resonance in Medicine. 1992; Works in progress: 1724.
13. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH et al. Detection of myelin breakdown products by proton magnetic resonance spectroscopy [letter]. Lancet 1993; 341: 630-1.
14. Dawson JW. The histology of disseminated sclerosis. Trans R Soc Edinb 1916; 50: 517-40.
15. Frahm J, Merboldt KD, Hânicke W. Localized proton spectroscopy using stimulated echoes. J Magn Reson 1987; 72: 502-8.
16. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hânicke W, Sauter R. Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn Reson Med 1989a; 9: 79-93.
17. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hänicke W, Sauter R. Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magn Reson Med 1989; 11: 47-63.
18. Frahm J, Michaelis T, Merboldt KD, Bruhn H, Gyngell ML, Hänicke W. Improvements in localized proton NMR spectroscopy of human brain, water suppression, short echo times and 1 ml resolution. J Magn Reson 1990; 290: 464-73.
19. Frommann C. Untersuchungen über die normale und pathologische anatomie des rückenmarks. Zweiter theil 1867; Jena: Frierich Frommann; 125.
20. Grossman RI, Lenkinski RE, Ramer KN, Gonzales-Scarano F, Cohen JA. MR proton spectroscopy in multiple sclerosis. AJNR 1992; 13: 1535-43.
21. Hawkins CP, Munro PMG, MacKenzie F, Kesselring J, Tofts PS, Du Boulay EP et al. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers. Brain 1990; 113: 365-78.
22. IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial [see comments]. Neurology 1993; 43: 655-61. Comment in: Neurology 1993; 43: 641-3.
23. Inglis BA, Brenner RE, Munro PMG, Williams SCR, McDonald WI, Sales KD. Measurement of proton NMR relaxation times for NAA, Cr, and Cho in acute EAE. In: Proceedings of the Eleventh Annual Meeting of the Society for Magnetic Resonance in Medicine. Book of Abstracts 1992; Works in progress: 2162.
24. Katz D, Taubenberger J, Raine C, McFarlin D, McFarland H. Gadolinium-enhancing lesions on magnetic resonance imaging: neuropathological findings [abstract]. Ann Neurol 1990; 28: 243.
25. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between MRI findings and lesion development in chronic active multiple sclerosis. Ann Neurol 1993; 34: 661-9.
26. Kauppinen RA, Nissinen T, Kärkkäinen A-M, Pirttilâ TRM, Palvimo J, Kokko H et al. Detection of thymosin ß4 in situ in a guinea pig cerebral cortex preparation using 1H NMR spectroscopy. J Biol Chem 1992; 267: 9905-10.
27. Kermode AG, Thomson AJ, Tofts PS, MacManus DG, Kendall BE, Kingsley DPE et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain 1990; 113: 1477-89.
28. Koopmans RA, Li DKB, Zhu G, Allen PS, Penn A, Paty DW. Magnetic resonance spectroscopy of multiple sclerosis: in-vivo detection of myelin breakdown product [letter]. Lancet 1993; 341: 631-2.
29. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
30. Larsson HBW, Frederiksen J, Kjaer L, Henriksen O, Olesen J. In vivo determination of T, and T2 in the brain of patients with severe but stable multiple sclerosis. Magn Reson Med 1988; 7: 43-55.
31. Larsson HBW, Christiansen P, Jensen M, Frederiksen J, Heltberg A, Olesen J et al. Localized in vivo proton spectroscopy in the brain of patients with multiple sclerosis. Magn Reson Med 199; 22: 23-31.
32. Lumsden CE. The neuropathology of multiple sclerosis. In Vincken PJ, Bruyn GW, editors. Handbook of clinical neurology. Amsterdam: North Holland, 1970; 9: 217-309.
33. McDonald WI, Miller DHM, Barnes D. The pathological evolution of multiple sclerosis [review], Neuropathol Appl Neurobiol 1992; 18: 319-34.
34. McDwain H, Bachelard HS. Biochemistry and the central nervous system. 5th ed. Edinburgh: Churchill Livingstone, 1985: 282-335.
35. Matthews PM, Francis G, Antel J, Arnold DL. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis [published erratum appears in Neurology 1991; 41: 1828], Neurology 1991; 41: 1251-6.
36. May GL, Wright LC, Holmes KT, Williams PG, Smith ICP, Wright PE et al. Assignment of methylene proton resonances in NMR spectra of embryonic and transformed cells to plasma membrane triglyceride. J Biol Chem 1986; 261: 3048-53.
37. Miller DH, Austin SJ, Connelly A, Youl BD, Gadian DG, McDonald WI. Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis [letter]. Lancet 1991; 337: 8-9.
38. Miller DH, Thompson AJ, Morrissey SP, MacManus DG, Moore SG, Kendall BE et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992; 55: 450-3.
39. Minderhoud JM, Mooyaart EL, Kamman RL, Teelken AW, Hoogstraten MC, Vencken LM et al. In vivo phosphorus magnetic resonance spectroscopy in multiple sclerosis. Arch Neurol 1992; 49: 161-5.
40. Narayana PA, Wolinsky JS, Jackson EF, McCarthy M. Proton MR spectroscopy of gadolinium-enhanced multiple sclerosis plaques. J Magn Reson Imag 1992; 2: 263-70.
41. Patel TB, Clark JB. Synthesis of /V-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J 1979; 184: 539-46.
42. Paty DW, Li DKB Interferon beta-lb is effective in relapsing-remitting multiple sclerosis, n. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group [see comments]. Comment in Neurology 1993; 3: 641 -3. Neurology 1993; 43: 662-7.
43. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
44. Poser S, Lüer W, Bruhn H, Frahm J, Brück Y, Felgenhauer K. Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 1992; 86: 579-85.
45. Prineas JW, Barnard RO, Revesz T, Kwon EE, Sharer L, Cho E-S. Multiple sclerosis: pathology of recurrent lesions. Brain 1993; 116: 681-93.
46. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of V-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37-45.
47. Stehbens WE. Pathology of the cerebral blood vessels. St Louis: Mosby. 1972.
48. Unrejak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993; 13 (3): 981-9.
49. Van Hecke P, Marchai G, Johannik K, Demaerel P, Wilms G, Carton H et al. Human brain proton localized NMR spectroscopy in multiple sclerosis. Magn Reson Med 1991; 18: 199 -206.
50. Wolinsky JS, Narayana PA, Fenstermacher MJ. Proton magnetic resonance spectroscopy in multiple sclerosis. Neurology 1990; 40: 1764-79.